XETR
ILM1
Market cap299mUSD
Oct 07, Last price
10.46EUR
1D
-3.68%
1Q
-13.98%
Jan 2017
34.10%
Name
Medios AG
Chart & performance
P/E
17.36
P/S
0.13
EPS
0.60
Div yield, %
—
Shrs. gr., 5y
9.37%
Rev. gr., 5y
27.11%
Revenues
2.08b
+10.39%
Net income
15m
+22.45%
CFO
43m
-41.62%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medios AG is a holding company, which engages in the provision of pharmaceutical drugs. It operates through the following segments: Pharmaceutical Supply, Patient-Specific Therapies, and Services. The Pharmaceutical Supply segment focuses on specialty pharmaceuticals for chronic and/or rare diseases. The Patient-Specific Therapies segment involves in the manufacturing of medications. The Services segment consists of the Groups other activities. The company was founded in 1980 and is headquartered in Berlin, Germany.
Related entities
Subsidiaries
Medios International B.V.
Key people
Falk Neukirch
Chief Financial Officer, Member of the Management Board · since 2021
Thomas Meier
Chief Executive Officer, Member of the Management Board · since 2026
Christoph Prusseit
Chief Innovation Officer, Member of the Management Board · since 2019
Anke Nestler
Deputy Chairwoman of the Supervisory Board · since 2023
Yann Samson
Chairman of the Supervisory Board · since 2014
Jens Apermann
Member of the Supervisory Board · since 2024
Florian Herger
Member of the Supervisory Board · since 2024
Joachim Messner
Member of the Supervisory Board · since 2023
Headquarters & legal address
Heidestraße 9
Berlin 10557
DE
Berlin 10557
DE
Previous name
CREVALIS CAPITAL AG
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||